Russell Investments Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,278
Closed -$6.92K 3912
2024
Q4
$6.92K Buy
2,278
+2,080
+1,051% +$9.06K ﹤0.01% 3217
2024
Q3
$1.03K Sell
198
-5
-2% -$25 ﹤0.01% 3476
2024
Q2
$522 Buy
203
+36
+22% +$123 ﹤0.01% 3498
2024
Q1
$822 Buy
+167
New +$989 ﹤0.01% 3154
2023
Q4
Sell
-182
Closed -$2.09K 3327
2023
Q3
$2.09K Sell
182
-58,493
-100% -$1.12M ﹤0.01% 3256
2023
Q2
$1.49M Buy
58,675
+30,271
+107% +$943K ﹤0.01% 1728
2023
Q1
$915K Sell
28,404
-51,094
-64% -$1.59M ﹤0.01% 2020
2022
Q4
$1.47M Sell
79,498
-74,730
-48% -$1.71M ﹤0.01% 1772
2022
Q3
$4.16M Buy
154,228
+118,685
+334% +$2.41M 0.01% 1147
2022
Q2
$490K Sell
35,543
-4,274
-11% -$65.8K ﹤0.01% 2279
2022
Q1
$775K Sell
39,817
-11,694
-23% -$177K ﹤0.01% 2075
2021
Q4
$840K Buy
+51,511
New +$859K ﹤0.01% 2242
2021
Q3
Sell
-5,835
Closed -$172K 3247
2021
Q2
$172K Hold
5,835
﹤0.01% 2949
2021
Q1
$163K Buy
+5,835
New +$161K ﹤0.01% 2882
2020
Q4
Sell
-52,050
Closed -$1.31M 3223
2020
Q3
$1.31M Buy
52,050
+15,054
+41% +$395K ﹤0.01% 1932
2020
Q2
$902K Buy
+36,996
New +$730K ﹤0.01% 2116
2019
Q4
Sell
-11,900
Closed -$155K 3147
2019
Q3
$155K Sell
11,900
-18,613
-61% -$228K ﹤0.01% 2696
2019
Q2
$396K Buy
+30,513
New +$385K ﹤0.01% 2338
2017
Q1
Sell
-8,290
Closed -$174K 3098
2016
Q4
$174K Buy
+8,290
New +$139K ﹤0.01% 2740

Other funds holding RVNC

Russell Investments Group's RVNC Position: Q1 2025 in Review

Russell Investments Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,278 shares — an estimated $6.92K sold.

Russell Investments Group first reported a position in RVNC in Q4 2016 and held it in 19 quarters. The position peaked at $4.16M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Russell Investments Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Russell Investments Group sold 2,278 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $6.92K.
  • Russell Investments Group first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 19 quarters.
  • Russell Investments Group's Revance Therapeutics, Inc. position peaked at $4.16M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Russell Investments Group's 13F filing for Q1 2025, filed 13 May 2025.